Correction: Evaluating the therapeutic efficacy of gastramide theranostics targeting cholecystokinin-2 receptors in a preclinical setting

MN Rahimi; JA Pinson; J Hilton-Proctor; J Van Zuylekom; B Blyth; PD Roselt; MB Haskali

Journal article

Correction: Evaluating the therapeutic efficacy of gastramide theranostics targeting cholecystokinin-2 receptors in a preclinical setting

MN Rahimi, JA Pinson, J Hilton-Proctor, J Van Zuylekom, B Blyth, PD Roselt, MB Haskali

Rsc Advances | Published : 2026

DOI: 10.1039/d6ra90008a

Abstract

Correction for ‘Evaluating the therapeutic efficacy of gastramide theranostics targeting cholecystokinin-2 receptors in a preclinical setting’ by Marwa N. Rahimi et al., RSC Adv., 2026, 16, 2123–2132, https://doi.org/10.1039/D5RA08789A.

University of Melbourne Researchers

Marwa Rahimi Author

Jo Pinson Author

Benjamin Blyth Author

Peter Roselt Author

Related Projects (1)

DEVELOPMENT OF INNOVATIVE FOLDAMERS FOR THE PEPTIDE RECEPTOR RADIONUCLIDE THERAPY OF TUMOURS OVEREXPRESSING CHOLECYSTOKININ-2 RECEPTORS

Peptide Receptor Radionuclide Therapy (PRRT) is a systematic treatment used to deliver high levels of radiation to cancer using radiopharmac..

Grants

Awarded by National Health and Medical Research Council

Keywords

5.2 Cellular and Gene Therapies

34 Chemical Sciences